Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron plus Rebetol in chronic hepatitis C genotype 1 Pegasys non-responders
2004-001220-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of peginterferon alfa-2b and ribavirin in chronic hepatitis C virus infection, sponsored by Merck & Co. Primary endpoint: Sustained virological response at 24 weeks post end of treatment. Started Dec 2004; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on 2004-001220-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001220-20.